Entera Bio Stock Today
| ENTX Stock | USD 1.35 0.02 1.46% |
PerformanceWeakest
| Odds Of DistressSmall
|
Entera Bio is trading at 1.35 as of the 3rd of March 2026; that is 1.46 percent decrease since the beginning of the trading day. The stock's open price was 1.37. Entera Bio has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 3rd of December 2025 and ending today, the 3rd of March 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of June 2018 | Category Healthcare | Classification Health Care |
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. The company has 45.86 M outstanding shares of which 117.64 K shares are currently shorted by private and institutional investors with about 0.5 trading days to cover. More on Entera Bio
Moving together with Entera Stock
Moving against Entera Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Entera Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEntera Bio utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Entera Bio's leverage profile, showing how much of Entera Bio's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Entera Bio (ENTX) is traded on NASDAQ Exchange in USA and employs 20 people. Entera Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 62.82 M. Entera Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 45.86 M outstanding shares of which 117.64 K shares are currently shorted by private and institutional investors with about 0.5 trading days to cover.
Entera Bio currently holds about 17.28 M in cash with (6.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6.
Check Entera Bio Probability Of Bankruptcy
Ownership AllocationEntera Bio holds a total of 45.86 Million outstanding shares. Entera Bio retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Entera Ownership Details
Entera Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Jane Street Group Llc | 2025-09-30 | 30.5 K | |
| Geode Capital Management, Llc | 2025-09-30 | 21.1 K | |
| Bank Of America Corp | 2025-09-30 | 21 K | |
| Hightower Advisors, Llc | 2025-09-30 | 18.1 K | |
| Gsa Capital Partners Llp | 2025-12-31 | 11.9 K | |
| Xtx Topco Ltd | 2025-09-30 | 10.8 K | |
| Ubs Group Ag | 2025-09-30 | 10.5 K | |
| Pnc Financial Services Group Inc | 2025-09-30 | 10 K | |
| Cubist Systematic Strategies, Llc | 2025-09-30 | 4.7 K | |
| Knoll Capital Management Lp | 2025-12-31 | 5.9 M | |
| Point72 Asset Management, L.p. | 2025-09-30 | 1.2 M |
Entera Bio Historical Income Statement
Entera Stock Against Markets
Entera Bio Corporate Management
| Hillel MBA | Chief Officer | Profile | |
| Miranda MBA | CEO Director | Profile | |
| II MD | Chief Officer | Profile | |
| Gregory Burshtein | Chief Development | Profile | |
| Dana CPA | Chief Officer | Profile | |
| Rachel Wagman | Chief Advisor | Profile | |
| RPh Itin | Head Bioanalytics | Profile |
Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.